Avita Medical Inc. Common Stock (RCEL)
Stock · NASDAQ · Health Care
$13.05as of 10/16/2026
Price chart
Active signals
RCEL Signal Track Record
How signals performed across all stocks →What RCEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | 0.0% | 49% | September 14, 2026 |
| Bollinger Band Breakout | 25 | 0.0% | 48% | October 2, 2026 |
| Bollinger Band Breakdown | 18 | -1.9% | 44% | March 18, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +0.4% | 50% | June 29, 2026 |
| Any 20-session window (baseline) | +1.2% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also p…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 226
- Website
- www.avitamedical.com/
Fundamentals
- 1-day range
- $12.95$13.47
- Market cap
- $146.19M
- P/E (trailing)
- —
- P/E (forward)
- -31.25
- EPS (trailing)
- $-1.44
- Dividend yield
- —
- Beta
- 2.07
- Avg. volume
- 439.9K
How Avita Medical Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Avita Medical Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RCELAvita Medical Inc. Common Stock$13.04▼ 2.76%Market cap $146.19MP/E —$3.22$13.73
- STIMNeuronetics Inc. Common Stock$1.88▼ 3.33%Market cap $156.57MP/E —$0.8$3.44
- CVRXCVRx Inc. Common Stock$1.3▼ 6.47%Market cap $157.62MP/E —$1.28$11.3
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3▼ 0.99%Market cap $163.52MP/E —$2.86$6.61
- MBOTMicrobot Medical Inc. Common Stock$0.95▲ 0.00%Market cap $120.90MP/E —$0.99$3.04
- APYXApyx Medical Corporation Common Stock$2.55▼ 0.39%Market cap $174.35MP/E —$2.32$5.08
- GUTSFractyl Health Inc. Common Stock$1.55▼ 62.74%Market cap $108.99MP/E —$3.78$29.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RCEL Avita Medical Inc. Common Stock | $146.19M | — | $13.04 | ▼ 2.76% | $3.22$13.73 |
| STIM Neuronetics Inc. Common Stock | $156.57M | — | $1.88 | ▼ 3.33% | $0.8$3.44 |
| CVRX CVRx Inc. Common Stock | $157.62M | — | $1.3 | ▼ 6.47% | $1.28$11.3 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3 | ▼ 0.99% | $2.86$6.61 |
| MBOT Microbot Medical Inc. Common Stock | $120.90M | — | $0.95 | ▲ 0.00% | $0.99$3.04 |
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $2.55 | ▼ 0.39% | $2.32$5.08 |
| GUTS Fractyl Health Inc. Common Stock | $108.99M | — | $1.55 | ▼ 62.74% | $3.78$29.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15benzinga · 10/12/2026
- AVITA Medical (RCEL) Stock Sees Fair Value Lift After PermeaDerm Data And Q2 BeatYahoo · 10/1/2026
- AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- David D. O'Toole · June 12, 2026 · Buy2.0K @ $3.97
- David D. O'Toole · June 12, 2026 · Grant2.0K @ $3.97
- Joseph Fralin Woody · June 9, 2026 · Buy5.2K @ $4
- Joseph Fralin Woody · June 9, 2026 · Buy5.0K @ $4.2
- Joseph Fralin Woody · June 3, 2026 · Buy5.0K @ $4.1
- Joseph Fralin Woody · June 2, 2026 · Buy5.0K @ $4.18
- Joseph Fralin Woody · June 1, 2026 · Buy5.0K @ $4.34
- Cary Guy Vance · May 29, 2026 · Grant5.0K @ $3.05
- David D. O'Toole · May 29, 2026 · Grant5.0K @ $3.05
- David D. O'Toole · May 20, 2026 · Buy2.0K @ $4.26
- David D. O'Toole · May 19, 2026 · Buy2.0K @ $4.24
Institutional Ownership
March 31, 2026
- Total shares held
- 86.89M
- Total value held
- $214.95M
- Institutional holders
- 75
- Unknown82.01M
- Unknown1.34M
- Unknown1.13M
- Unknown543.0K
- Unknown429.0K
- Unknown183.2K
- Unknown157.6K
- Unknown100.0K
- Unknown99.8K
- Unknown94.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat
PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.